Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | MMP1 | P03956 | 4/20 | 0.42 |
| ▸ | MMP9 | P14780 | 3/20 | 0.42 |
| ▸ | MMP8 | P22894 | 3/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.42 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetoacetic Acid SCHEMBL9689813 | 0.87 | THRB (0.40) | CA4THRBMEN1KMT2AMMP2 | |
| Oxalic Acid SCHEMBL29422639 | 0.82 | MEN1 (0.56) | CA4THRBMEN1KMT2AMMP2 | |
| Oxalic Acid SCHEMBL965059 | 0.82 | MEN1 (0.56) | CA4THRBMEN1KMT2AMMP2 | |
| Oxalic Acid SCHEMBL4859 | 0.82 | MEN1 (0.56) | CA4THRBMEN1KMT2AMMP2 | |
| Oxalic Acid SCHEMBL28195348 | 0.80 | MEN1 (0.53) | CA4THRBMEN1KMT2AMMP2 | |
| Oxalic Acid SCHEMBL28517984 | 0.80 | MEN1 (0.53) | CA4THRBMEN1KMT2AMMP2 | |
| Oxalic Acid SCHEMBL28020190 | 0.80 | MEN1 (0.53) | CA4THRBMEN1KMT2AMMP2 | |
| Oxalic Acid SCHEMBL28173309 | 0.80 | MEN1 (0.53) | CA4THRBMEN1KMT2AMMP2 | |
| Fosfonet SCHEMBL9687545 | 0.79 | MMP2 (0.42) | THRBMEN1KMT2AMMP2CA12 | |
| Oxalic Acid SCHEMBL29186473 | 0.77 | THRB (0.43) | THRBMEN1KMT2AMMP2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193434-A1 | Anti-tumor composition | AJINOMOTO CO. INC (JP) | 2002-12-19 | — | — | US | claimed |
| US-20020193362-A1 | Anti-tumor composition | AJINOMOTO CO. INC (JP) | 2002-12-19 | — | — | US | claimed |
| CN-119751480-A | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical compositions thereof, and combinations with anticancer agents | ITEOS比利时公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119486755-A | DLK1 antibodies and methods of treating cancer | 加利福尼亚大学校董会 | 2025-02-18 | — | — | CN | disclosed |
| CN-113226324-B | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical compositions thereof, and combinations with anticancer agents | ITEOS比利时公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119212721-A | CDH17 antibodies and methods of treating cancer | 加利福尼亚大学校董会 | 2024-12-27 | — | — | CN | disclosed |
| CN-117136242-A | Compounds, compositions and methods of treatment thereof | ITEOS比利时公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-116570628-A | Clostridium northwest for treating solid tumors in humans | 生物医学谷探索股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116410318-A | anti-AXL antagonistic antibodies | 卑尔根技术锻造股份公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-105451750-B | Clostridium noeukii for the treatment of solid tumors in humans | 生物医学谷探索股份有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-107531786-B | anti-AXL antagonist antibodies | 卑尔根技术锻造股份公司（NO） | 2023-01-13 | — | — | CN | disclosed |
| US-7655696-B2 | Highly efficacious and highly safe composition of a Stilbene derivative and a platinum coordination compound cis-diaminedichloroplatinum (II) | AJINOMOTO CO., INC. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20090093540-A1 | ANTI-TUMOR COMPOSITION | AJINOMOTO CO., INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-1068870-B1 | ANTITUMOR AGENTS | AJINOMOTO KK (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-6992106-B2 | Anti-tumor composition | AJINOMOTO CO., INC. (JP) | 2006-01-31 | — | — | US | disclosed |
| US-20050281892-A1 | Highly efficacious and highly safe composition of a Stilbene derivative and a platinum coordination compound cis-diaminedichloroplatinum (II) | AJINOMOTO CO., INC. (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20020193434-A1 | Anti-tumor composition | AJINOMOTO CO. INC (JP) | 2002-12-19 | — | — | US | disclosed |
| US-20020193362-A1 | Anti-tumor composition | AJINOMOTO CO. INC (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6462087-B1 | Anti-tumor composition | AJINOMOTO CO., INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-1068870-A1 | ANTITUMOR AGENTS | Ajinomoto Co., Inc. (JP) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193434-A1 | Anti-tumor composition | TP53, VHL, MKI67 | CA4 162/4885THRB 2902/4885MEN1 908/4885 |
| US-20050281892-A1 | Highly efficacious and highly safe composition of a Stilbene derivative and a platinum coordination compound cis-diaminedichloroplatinum (II) | MSH2, TOP2B, TP53 | CA4 1079/4885THRB 3940/4885MEN1 212/4885 |
| US-20020193362-A1 | Anti-tumor composition | TP53, VHL, MKI67 | CA4 162/4885THRB 2902/4885MEN1 908/4885 |
| US-20090093540-A1 | ANTI-TUMOR COMPOSITION | TP53, VHL, MKI67 | CA4 184/4885THRB 2922/4885MEN1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.